BSP Receives FDA Approval for New ECG Technology

BSP Biological Signal Processing announced that it has received FDA approval for the marketing and sale of its HyperQ System. BSP, a company in the field of high-frequency electrocardiogram (HF ECG), has developed superior ECG technology, with breakthrough diagnostic value for detecting and monitoring ischemic heart diseases — the leading cause of death in the developed world. BSP's HyperQ System is a PC-based stress ECG device that records, analyses and displays both conventional stress ECG and HF ECG for detection of myocardial ischemia.
PR Newswire